Disseminated cysticercosis: clinical spectrum, Toll-like receptor-4 gene polymorphisms and role of albendazole: A prospective follow-up of 60 cases with a review of 56 published cases.
In this study, we describe clinical and imaging spectrum, and the natural course of patients with disseminated cysticercosis. How albendazole affects the course of disease has also been evaluated. We assessed the Toll-like receptor-4 gene polymorphisms, to know the reason for the apparently higher prevalence of disseminated cysticercosis in India.Sixty consecutive patients with disseminated cysticercosis were enrolled. Sixty age-and-sex-matched healthy controls were also enrolled for the purpose of genetic study. Twenty patients, who gave consent, were treated with albendazole along with corticosteroids. Forty patients did not give consent for antiparasitic therapy. Assessment for Toll-like receptor-4 gene polymorphisms (Asp299Gly and Thr399Ile genes) was done. Patients were followed for 6 months. We also performed a literature search of cases published in English language using PubMed electronic database and analyzed 56 cases thus available.There was an increased risk (6.63 fold and 4.61 fold) of disseminated cysticercosis in the presence of Asp299Gly and Thr399Ile polymorphisms in Toll-like receptor-4, respectively. The allelic frequency of Gly (11% vs. 3%, P = 0.024, odds ratio [OR] = 3.52) and Ile alleles (11% vs. 2%, P = 0.009, OR = 4.738) in disseminated cysticercosis was high. Albendazole resulted in complete disappearance of all cerebral lesions in 35% (7/20) patients and reduction in lesion load in remaining 65% (13/20) patients. No significant change in number of cysticercal lesion was noted in patients who did not receive albendazole. No major adverse reaction following antiparasitic treatment was noted. Three deaths were recorded in patients who did not receive antiparasitic treatment.Of the 56 cases reported in PubMed, 33 patients received antiparasitic treatment with follow-up data available for 31 patients. Most (24) of these patients received albendazole. A significant clinical and/or imaging improvements, on follow up, were observed in 27 patients. Of the 4 deaths recorded, 3 had a heavy parasitic load and died after praziquantel therapy.Toll-like receptor-4 gene polymorphisms are associated with an increased susceptibility to disseminated cysticercosis, in the Indian population. Albendazole treatment seems to reduce the lesion load and improve symptoms.
aDepartment of Neurology bDepartment of Microbiology cDepartment of Radiodiagnosis, King George Medical University dDepartment of Pathology, Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Abdul
A
Qavi
Ravindra Kumar
RK
Garg
Hardeep Singh
HS
Malhotra
Amita
A
Jain
Neeraj
N
Kumar
Kiran Preet
KP
Malhotra
Pradeep Kumar
PK
Srivastava
Rajesh
R
Verma
Praveen Kumar
PK
Sharma
D000328:Adult; D015766:Albendazole / Q000627:therapeutic use*; D000483:Alleles; D000818:Animals; D000923:Anticestodal Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D003551:Cysticercosis / Q000188:drug therapy* / Q000235:genetics* / Q000469:parasitology; D003552:Cysticercus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007194:India / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D015995:Prevalence; D011446:Prospective Studies; D051197:Toll-Like Receptor 4 / Q000235:genetics*; D016896:Treatment Outcome; D055815:Young Adult
D000923:Anticestodal Agents; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4; D015766:Albendazole
J Neurol Sci. 2015 Aug 15;355(1-2):180-5
26081118
Lancet Infect Dis. 2014 Aug;14(8):687-95
24999157
Bioinformatics. 2006 Aug 1;22(15):1928-9
16720584
Neurol India. 2004 Jun;52(2):171-7
15269463
Br Med J. 1926 Sep 11;2(3427):471-2
20772765
Br Med J. 1928 Dec 1;2(3543):980-2
20774301
Nucleic Acids Res. 1988 Feb 11;16(3):1215
3344216
Neurology. 2001 Jul 24;57(2):177-83
11480424
Brain. 1988 Jun;111 ( Pt 3):597-614
3382913
Am J Trop Med Hyg. 2012 Sep;87(3):381
22956716
Lancet Neurol. 2014 Dec;13(12):1202-15
25453460
N Engl J Med. 2004 Jan 15;350(3):249-58
14724304
J Infect Dis. 2010 Oct 15;202(8):1219-25
20807077
N Engl J Med. 2004 Jan 15;350(3):266
14724306
Arch Neurol. 2008 Feb;65(2):276-7
18268201
Br Med J. 1941 Aug 23;2(4207):263-5
20783826
Postgrad Med J. 1986 Apr;62(726):299-300
3714626
Clin Chem. 2006 Apr;52(4):728-36
16455867
J Clin Microbiol. 2011 Jan;49(1):23-6
21068275